Our brilliant panellists included Priya Baraniak, chief business officer at OrganaBio, Matthew Lakelin, vice president of scientific affairs and product development at TrakCel, and George Buchman, research fellow at Catalent Cell and Gene Therapy.
With the global cell and gene therapy market poised to reach a staggering $80 billion by 2029, these cutting-edge therapies have the potential to transform how we treat and potentially cure serious diseases such as cancers or genetic conditions.
In fact, in a recent survey, healthcare industry professionals also named cell and gene therapy as the area most likely to dominate the pharma industry in 2024.
Specifically, oncology is also expected to maintain its lead as the key area for major development, predicted to account for 44% of the market by 2029.
However, these treatments pose significant manufacturing challenges – from scaling up to reach a larger patient population, reducing production time and bringing down overall cost.
This panel discussion aims to shed light on the most pressing and difficult issues within the industry and how we might solve them, as well as providing an optimistic outlook moving forward.
